Edition:
United States

Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

124.95USD
16 Aug 2019
Change (% chg)

$2.98 (+2.44%)
Prev Close
$121.97
Open
$123.35
Day's High
$126.19
Day's Low
$123.12
Volume
1,239,233
Avg. Vol
1,170,807
52-wk High
$165.87
52-wk Low
$95.21

Select another date:

Thu, Aug 8 2019

Sarepta says adverse event report for DMD gene therapy erroneously submitted

Sarepta Therapeutics Inc said on Thursday it was informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD).

UPDATE 1-Patient in Sarepta gene therapy trial develops serious illness; shares plunge

Aug 8 Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD) was reported to have developed a serious illness.

Patient in Sarepta gene therapy trial develops serious illness; shares plunge

Aug 8 Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy was reported to have developed a serious illness.

Sarepta surges after Pfizer gene therapy data raises safety concerns

Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc .

UPDATE 2-Sarepta surges after Pfizer gene therapy data raises safety concerns

June 28 Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc.

Sarepta shares rise after gene therapy deal, promising data

Sarepta Therapeutics Inc beefed up its gene therapies portfolio through the purchase of its partner Myonexus Therapeutics Inc and reported positive data for a genetic disorder therapy from the privately held company, sending its shares up 9 percent on Wednesday.

UPDATE 1-Sarepta to buy Myonexus for $165 mln in gene therapy push

Feb 27 Sarepta Therapeutics Inc said on Wednesday it would buy privately held gene therapy company Myonexus Therapeutics Inc for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.

Sarepta to buy gene therapy developer Myonexus for $165 mln

Feb 27 Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.

Select another date: